S&P 500   2,986.20 (-0.39%)
DOW   26,770.20 (-0.95%)
QQQ   192.03 (-0.79%)
AAPL   236.13 (+0.36%)
FB   185.92 (-2.35%)
MSFT   138.05 (-1.17%)
AMZN   1,763.32 (-1.35%)
CGC   20.00 (-3.66%)
NVDA   190.73 (-1.83%)
MU   43.47 (-4.46%)
TSLA   256.90 (-1.94%)
T   38.23 (+1.08%)
ACB   3.71 (-4.63%)
NFLX   275.30 (-6.15%)
BAC   30.45 (+0.63%)
GILD   64.23 (-1.53%)
S&P 500   2,986.20 (-0.39%)
DOW   26,770.20 (-0.95%)
QQQ   192.03 (-0.79%)
AAPL   236.13 (+0.36%)
FB   185.92 (-2.35%)
MSFT   138.05 (-1.17%)
AMZN   1,763.32 (-1.35%)
CGC   20.00 (-3.66%)
NVDA   190.73 (-1.83%)
MU   43.47 (-4.46%)
TSLA   256.90 (-1.94%)
T   38.23 (+1.08%)
ACB   3.71 (-4.63%)
NFLX   275.30 (-6.15%)
BAC   30.45 (+0.63%)
GILD   64.23 (-1.53%)
Log in

Puma Biotechnology News Headlines (NASDAQ:PBYI)

$6.50
-0.18 (-2.69 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
$6.47
Now: $6.50
$6.70
50-Day Range
$6.79
MA: $10.17
$12.27
52-Week Range
$6.47
Now: $6.50
$45.50
Volume1.80 million shs
Average Volume1.28 million shs
Market Capitalization$252.83 million
P/E RatioN/A
Dividend YieldN/A
Beta1.6

Headlines

Puma Biotechnology (NASDAQ PBYI) News Headlines

Source:
DateHeadline
Puma Biotechnology Inc (NASDAQ:PBYI) Expected to Post Earnings of -$0.76 Per SharePuma Biotechnology Inc (NASDAQ:PBYI) Expected to Post Earnings of -$0.76 Per Share
www.americanbankingnews.com - October 18 at 9:36 AM
Puma Biotechnology Inc (NASDAQ:PBYI) Sees Significant Drop in Short InterestPuma Biotechnology Inc (NASDAQ:PBYI) Sees Significant Drop in Short Interest
www.americanbankingnews.com - October 15 at 3:43 PM
How Much Did Puma Biotechnology, Inc.'s (NASDAQ:PBYI) CEO Pocket Last Year?How Much Did Puma Biotechnology, Inc.'s (NASDAQ:PBYI) CEO Pocket Last Year?
finance.yahoo.com - October 10 at 3:53 PM
Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive RisksGoldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks
finance.yahoo.com - October 8 at 5:03 PM
Heres Why Puma Biotechnology Tumbled TodayHere's Why Puma Biotechnology Tumbled Today
www.fool.com - October 8 at 12:03 PM
Puma Biotechnology (NASDAQ:PBYI) Downgraded to Sell at Goldman Sachs GroupPuma Biotechnology (NASDAQ:PBYI) Downgraded to Sell at Goldman Sachs Group
www.americanbankingnews.com - October 8 at 9:15 AM
The Week Ahead In Biotech: Pfenex And Clinuvel On The Radar Ahead of FDA Decisions, 2 IPOs On DeckThe Week Ahead In Biotech: Pfenex And Clinuvel On The Radar Ahead of FDA Decisions, 2 IPOs On Deck
finance.yahoo.com - October 6 at 10:07 PM
Puma Stock Jumps as Biotech Gets Good News From the FDAPuma Stock Jumps as Biotech Gets Good News From the FDA
www.barrons.com - October 3 at 9:13 AM
Puma Biotechnology: A Speculative Investment At A DiscountPuma Biotechnology: A Speculative Investment At A Discount
seekingalpha.com - October 2 at 4:45 PM
Puma Biotechnology +13% after FDA OKs Nerlynx label additionPuma Biotechnology +13% after FDA OKs Nerlynx label addition
seekingalpha.com - October 2 at 4:45 PM
Puma Biotechnology Inc (NASDAQ:PBYI) Given Consensus Rating of "Hold" by BrokeragesPuma Biotechnology Inc (NASDAQ:PBYI) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - September 29 at 11:51 AM
Puma Biotechnology Inc (NASDAQ:PBYI) Expected to Announce Quarterly Sales of $60.93 MillionPuma Biotechnology Inc (NASDAQ:PBYI) Expected to Announce Quarterly Sales of $60.93 Million
www.americanbankingnews.com - September 27 at 1:28 AM
Puma Biotechnology Inc (NASDAQ:PBYI) Expected to Announce Earnings of -$0.76 Per SharePuma Biotechnology Inc (NASDAQ:PBYI) Expected to Announce Earnings of -$0.76 Per Share
www.americanbankingnews.com - September 25 at 8:50 PM
Insider Selling: Puma Biotechnology Inc (NASDAQ:PBYI) Insider Sells 1,711 Shares of StockInsider Selling: Puma Biotechnology Inc (NASDAQ:PBYI) Insider Sells 1,711 Shares of Stock
www.americanbankingnews.com - September 25 at 7:03 PM
Do Options Traders Know Something About Puma Biotech (PBYI) Stock We Dont?Do Options Traders Know Something About Puma Biotech (PBYI) Stock We Don't?
www.msn.com - September 16 at 8:36 PM
Do Options Traders Know Something About Puma Biotech (PBYI) Stock We Don't?Do Options Traders Know Something About Puma Biotech (PBYI) Stock We Don't?
finance.yahoo.com - September 16 at 4:26 PM
Puma Biotechs sNDA for Nerlynx Combo Gets FDA AcceptancePuma Biotech's sNDA for Nerlynx Combo Gets FDA Acceptance
finance.yahoo.com - September 14 at 6:18 AM
FDA accepts Pumas application for expanded use of NerlynxFDA accepts Puma's application for expanded use of Nerlynx
seekingalpha.com - September 11 at 5:56 PM
Puma Biotechnology (NASDAQ:PBYI) Has Debt But No Earnings; Should You Worry?Puma Biotechnology (NASDAQ:PBYI) Has Debt But No Earnings; Should You Worry?
finance.yahoo.com - September 11 at 5:56 PM
Puma Biotechnology Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast CancerPuma Biotechnology Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
finance.yahoo.com - September 11 at 5:56 PM
Why Is Puma Biotech (PBYI) Up 16.8% Since Last Earnings Report?Why Is Puma Biotech (PBYI) Up 16.8% Since Last Earnings Report?
finance.yahoo.com - September 8 at 7:58 AM
Puma Bios Nerlynx OKd in ArgentinaPuma Bio's Nerlynx OK'd in Argentina
seekingalpha.com - September 5 at 1:01 PM
Puma Biotechnology Licensing Partner Pint Pharma Receives Marketing Authorization for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive, HER2-Positive Breast CancerPuma Biotechnology Licensing Partner Pint Pharma Receives Marketing Authorization for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive, HER2-Positive Breast Cancer
finance.yahoo.com - September 5 at 1:00 PM
What This Recent FDA Move Could Mean for Breast Cancer Patients With Brain MetastasesWhat This Recent FDA Move Could Mean for Breast Cancer Patients With Brain Metastases
247wallst.com - September 4 at 10:41 AM
Pumas Breast Cancer Drug Accorded Orphan Drug Designation For Brain MetastasesPuma's Breast Cancer Drug Accorded Orphan Drug Designation For Brain Metastases
www.benzinga.com - September 4 at 10:41 AM
Puma Bio up 9% on Orphan Drug tag for Nerlynx for certain breast cancer patientsPuma Bio up 9% on Orphan Drug tag for Nerlynx for certain breast cancer patients
seekingalpha.com - September 3 at 7:13 PM
FDA Grants Orphan Drug Designation to Puma Biotechnology’s NERLYNX® for the Treatment of Breast Cancer Patients with Brain MetastasesFDA Grants Orphan Drug Designation to Puma Biotechnology’s NERLYNX® for the Treatment of Breast Cancer Patients with Brain Metastases
www.businesswire.com - September 3 at 7:13 PM
Puma Biotech stock surges on FDA cancer drug designationPuma Biotech stock surges on FDA cancer drug designation
finance.yahoo.com - September 3 at 7:13 PM
Edited Transcript of PBYI earnings conference call or presentation 8-Aug-19 8:30pm GMTEdited Transcript of PBYI earnings conference call or presentation 8-Aug-19 8:30pm GMT
finance.yahoo.com - August 14 at 7:11 PM
Cellulite Treatment Market Projected To Reach $1,438.5 Billion By 2026Cellulite Treatment Market Projected To Reach $1,438.5 Billion By 2026
www.marketwatch.com - August 12 at 9:55 AM
Puma Biotechnology Inc (PBYI) Q2 2019 Earnings Call TranscriptPuma Biotechnology Inc (PBYI) Q2 2019 Earnings Call Transcript
www.fool.com - August 12 at 3:35 AM
Puma up 24% after hours on Q2 beat, Nerlynx sales up 6%Puma up 24% after hours on Q2 beat, Nerlynx sales up 6%
seekingalpha.com - August 8 at 8:01 PM
Interesting PBYI Put And Call Options For March 2020Interesting PBYI Put And Call Options For March 2020
www.nasdaq.com - August 8 at 8:01 PM
Should You Be Worried About Insider Transactions At Puma Biotechnology, Inc. (NASDAQ:PBYI)?Should You Be Worried About Insider Transactions At Puma Biotechnology, Inc. (NASDAQ:PBYI)?
finance.yahoo.com - August 8 at 8:01 PM
Puma Biotechnology Reports Second Quarter 2019 Financial ResultsPuma Biotechnology Reports Second Quarter 2019 Financial Results
finance.yahoo.com - August 8 at 8:01 PM
Puma Biotechnology Q2 2019 Earnings PreviewPuma Biotechnology Q2 2019 Earnings Preview
seekingalpha.com - August 8 at 7:37 AM
Heres Why Puma Biotechnology Fell 24.1% in JulyHere's Why Puma Biotechnology Fell 24.1% in July
www.fool.com - August 8 at 7:37 AM
Here's Why Puma Biotechnology Fell 24.1% in JulyHere's Why Puma Biotechnology Fell 24.1% in July
finance.yahoo.com - August 8 at 7:37 AM
Puma Biotech (PBYI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleasePuma Biotech (PBYI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
finance.yahoo.com - August 1 at 7:53 PM
Keytruda data in TNBC modestly pressures Puma Bio, down 3%Keytruda data in TNBC modestly pressures Puma Bio, down 3%
seekingalpha.com - July 29 at 10:26 PM
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - July 25 at 8:14 PM
Knight Therapeutics Announces Health Canada Has Approved NERLYNX ® for Early-Stage Breast CancerKnight Therapeutics Announces Health Canada Has Approved NERLYNX ® for Early-Stage Breast Cancer
finance.yahoo.com - July 16 at 6:33 PM
Puma Bio up 5% after hours on Nerlynx nod in CanadaPuma Bio up 5% after hours on Nerlynx nod in Canada
seekingalpha.com - July 16 at 6:33 PM
Knight Therapeutics Announces Health Canada Has Approved NERLYNX ® for Early-Stage Breast CancerKnight Therapeutics Announces Health Canada Has Approved NERLYNX ® for Early-Stage Breast Cancer
finance.yahoo.com - July 16 at 6:33 PM
Puma Biotechnology’s Licensing Partner Knight Therapeutics Receives Regulatory Approval from Health Canada to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of Hormone Receptor Positive, HER2-Positive Early Stage Breast CancerPuma Biotechnology’s Licensing Partner Knight Therapeutics Receives Regulatory Approval from Health Canada to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of Hormone Receptor Positive, HER2-Positive Early Stage Breast Cancer
finance.yahoo.com - July 16 at 6:33 PM
Implied Volatility Surging for Puma Biotech (PBYI) Stock OptionsImplied Volatility Surging for Puma Biotech (PBYI) Stock Options
finance.yahoo.com - July 5 at 5:46 PM
Puma Biotechnology Presents Interim Results from the Biliary Tract Cohort of its Phase II SUMMIT Basket Trial of Neratinib at the ESMO World Congress on Gastrointestinal Cancer 2019Puma Biotechnology Presents Interim Results from the Biliary Tract Cohort of its Phase II SUMMIT Basket Trial of Neratinib at the ESMO World Congress on Gastrointestinal Cancer 2019
finance.yahoo.com - July 3 at 6:09 PM
Puma Biotech Submits sNDA for Breast Cancer Drug NerlynxPuma Biotech Submits sNDA for Breast Cancer Drug Nerlynx
finance.yahoo.com - July 2 at 6:04 PM
Puma Bio files U.S. marketing application for expanded use of NerlynxPuma Bio files U.S. marketing application for expanded use of Nerlynx
seekingalpha.com - July 1 at 6:05 PM
Puma Biotechnology Submits a Supplemental New Drug Application to U.S. FDA for Neratinib to Treat HER2-Positive Metastatic Breast CancerPuma Biotechnology Submits a Supplemental New Drug Application to U.S. FDA for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
finance.yahoo.com - July 1 at 9:03 AM
This page was last updated on 10/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel